<p>M&amp;T Bank Corp 在最近向美国证券交易委员会提交的 13F 文件中表示，在第四季度将其在麦克森公司（NYSE:MCK - 免费报告）的持股比例提高了 263.9%。该公司在此期间购买了额外的 60,683 股后，持有该公司 83,674 股股票。M&amp;T Bank Corp 在最近的报告期末持有麦克森约 0.07% 的股份，价值 68,637,000 美元。</p>
<ul>
<li>3 只可能下一个宣布股票拆分的股票</li>
</ul>
<p>其他一些对冲基金和机构投资者最近也增加或减少了在该公司的持股。Obsidian Personal Planning Solutions LLC 在第三季度将其在麦克森的持股比例提高了 2.9%。Obsidian Personal Planning Solutions LLC 现在持有 426 股该公司的股票，价值 346,000 美元，此前在此期间购买了额外的 12 股。IAM Advisory LLC 在第三季度将其在麦克森的持股比例提高了 0.3%。IAM Advisory LLC 现在持有 3,908 股该公司的股票，价值 3,019,000 美元，此前在此期间购买了额外的 13 股。PDS Planning Inc 在第三季度将其在麦克森的持股比例提高了 1.1%。PDS Planning Inc 现在持有 1,209 股该公司的股票，价值 934,000 美元，此前在此期间购买了额外的 13 股。Berkshire Asset Management LLC PA 在第三季度将其在麦克森的持股比例提高了 4.6%。Berkshire Asset Management LLC PA 现在持有 294 股该公司的股票，价值 227,000 美元，此前在此期间购买了额外的 13 股。最后，Norden Group LLC 在第四季度将其在麦克森的持股比例提高了 4.3%。Norden Group LLC 现在持有 317 股该公司的股票，价值 260,000 美元，此前在此期间购买了额外的 13 股。机构投资者和对冲基金持有该公司 85.07% 的股份。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些研究公司最近对 MCK 进行了评论。摩根士丹利在 1 月 29 日的研究报告中重申了 “增持” 评级，并对麦克森的股票设定了 966.00 美元的目标价。TD Cowen 在 2 月 5 日的研究报告中将麦克森的目标价从 1,000.00 美元提高至 1,012.00 美元，并给予该股票 “买入” 评级。Leerink Partners 在 3 月 5 日的研究报告中重申了 “跑赢大盘” 评级，并对麦克森的股票设定了 1,085.00 美元的目标价。罗伯特·W·贝尔德在 1 月 14 日的研究报告中设定了 968.00 美元的目标价。最后，Weiss Ratings 在 2 月 5 日的研究报告中将麦克森的股票评级从 “买入（a-）” 下调至 “买入（b+）”。十三位分析师对该股票给予了买入评级，三位分析师对该股票给予了持有评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，平均目标价为 970.93 美元。</p>
<ul>
<li>3 只安静提高分红的增长股票</li>
</ul>
<p><strong>查看我们关于麦克森的最新研究报告</strong></p>
<h2>影响麦克森的关键头条新闻</h2>
<p>以下是本周影响麦克森的关键新闻：</p>
<ul>
<li>积极情绪：阿波罗将以 12.5 亿美元收购麦克森医疗 - 外科解决方案业务的少数股权（约 13%）——验证了 MMS 分拆计划，为 IPO 提供流动性，并带来外部投资者的认可，可能降低分拆的风险。麦克森将少数股权出售给阿波罗基金，交易额为 12.5 亿美元</li>
<li>积极情绪：公司新闻稿/报道确认与阿波罗的最终协议，并将交易框架视为计划中的 MMS IPO 的里程碑——表明管理层正在执行分拆战略并释放价值。麦克森与阿波罗基金签署战略少数股权协议，涉及医疗 - 外科解决方案</li>
<li>积极情绪：分析师预计麦克森下个月将报告另一个强劲的季度，预计利润将实现两位数增长——如果结果超出预期，这将成为短期催化剂，可能逆转疲软。麦克森财报预览：预期是什么</li>
<li>中性情绪：长期分析师文章强调麦克森的复合增长记录（每股收益两位数增长和管理层的股东价值创造）——对关注多年回报的投资者支持，但对市场的即时影响较小。麦克森股票仍然是高信念的复合增长股吗？</li>
<li>中性情绪：独立比较和行业文章（例如，与 CONMED 的正面比较）提供了背景，但不太可能单独对股票产生实质性影响。麦克森与 CONMED 的正面比较</li>
<li>消极情绪：市场反应：报道指出麦克森今天的交易下跌幅度超过大盘——由于投资者消化 MMS 交易的细节、分拆的时机以及更广泛的市场走势，该股票已从近期高点回落。麦克森（MCK）下跌幅度超过大盘</li>
</ul>
<h2>麦克森股票下跌 1.9%</h2>
<ul>
<li>超过收益：5 只击败市场并提高分红的股票</li>
</ul>
<p>MCK 股票周三开盘价为 842.59 美元。麦克森公司 12 个月低点为 637.00 美元，12 个月高点为 999.00 美元。该公司的市值为 1,032.1 亿美元，市盈率为 24.23，PEG 比率为 1.24，贝塔值为 0.42。该公司的 50 日移动平均线为 910.28 美元，200 日移动平均线为 856.99 美元。</p>
<p>麦克森（NYSE:MCK - 获取免费报告）最近于 2 月 4 日（星期三）发布了其财报。公司报告本季度每股收益（EPS）为 9.34 美元，超出分析师一致预期的 9.19 美元，超出幅度为 0.15 美元。麦克森的净利润率为 1.09%，股本回报率为负的 338.97%。本季度公司收入为 1061.6 亿美元，而一致预期为 1059.8 亿美元。去年同期，公司每股收益为 8.03 美元。与去年同期相比，公司的收入增长了 11.4%。麦克森已将 2026 财年的指引设定为 38.800-39.200 的每股收益。研究分析师平均预计麦克森公司今年将发布 39.02 的每股收益。</p>
<h2>麦克森分红公告</h2>
<p>该公司最近宣布了一项季度分红，已于 4 月 1 日（星期三）支付。3 月 2 日（星期一）登记在册的股东获得每股 0.82 美元的分红。除息日期为 3 月 2 日（星期一）。这相当于年化分红为 3.28 美元，分红收益率为 0.4%。麦克森的分红支付比率（DPR）目前为 9.43%。</p>
<h2>麦克森内部买卖情况</h2>
<p>在其他消息中，首席会计官纳波利昂·B·鲁特利奇（Napoleon B. Rutledge, Jr.）于 2 月 6 日（星期五）出售了 328 股公司的股票，交易价格为每股 955.00 美元，总交易额为 313,240.00 美元。该交易已在向 SEC 提交的文件中披露，相关文件可通过此链接访问。此外，董事玛丽亚·马丁内斯（Maria Martinez）于 2 月 19 日（星期四）出售了 349 股公司的股票，交易价格为每股 939.87 美元，总交易额为 328,014.63 美元。交易后，该董事在公司持有 301 股，价值 282,900.87 美元。这代表其持股比例减少了 53.69%。该销售的 SEC 文件提供了更多信息。内部人士在上个季度共出售了 3,592 股公司股票，价值 3,518,555 美元。公司内部人士持有公司股票的比例为 0.08%。</p>
<h2>麦克森公司简介</h2>
<p>（免费报告）</p>
<p>麦克森公司（NYSE: MCK）是一家全球医疗服务和分销公司，提供药品、医疗外科产品和医疗技术解决方案。公司成立于 1833 年，总部位于德克萨斯州的欧文，麦克森在药品分销和医疗服务价值链中运营，连接制造商、药店、医院和医疗系统，以帮助管理药物和临床供应的流动。</p>
<p>公司的核心业务包括药品批发分销和物流、专业药房服务，以及向急性和非急性护理提供者提供医疗外科用品。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过麦克森</li>
</ul>
<p><strong>想知道其他对 MCK 感兴趣的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取麦克森公司（NYSE:MCK - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1DSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1DSw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在麦克森吗？</h2>
<p>在考虑麦克森之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而麦克森并不在名单上。</p>
<p>虽然麦克森目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

易方达沪深300医药ETF

标普生物技术 ETF - SPDR

生物科技ETF基金

<p>M&T Bank Corp 在第四季度将其在麦克森公司（NYSE:MCK）的持股增加了 263.9%，在购买了 60,683 股后，现持有 83,674 股。其他机构投资者也调整了他们的持股。分析师们对该公司的前景持积极态度，多家机构给予买入评级，目标价范围在 968 美元到 1,085 美元之间。预计麦克森将报告强劲的盈利增长，最近与阿波罗基金达成的对其医疗外科解决方案业务的少数股权投资被视为迈向首次公开募股的积极一步</p>

<p>M&amp;T Bank Corp increased its position in McKesson Corporation (NYSE:MCK - Free Report) by 263.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 83,674 shares of the company's stock after purchasing an additional 60,683 shares during the period. M&amp;T Bank Corp owned about 0.07% of McKesson worth $68,637,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>M&amp;T Bank Corp 在最近向美国证券交易委员会提交的 13F 文件中表示，在第四季度将其在麦克森公司（NYSE:MCK - 免费报告）的持股比例提高了 263.9%。该公司在此期间购买了额外的 60,683 股后，持有该公司 83,674 股股票。M&amp;T Bank Corp 在最近的报告期末持有麦克森约 0.07% 的股份，价值 68,637,000 美元。</p>
</div><ul>
<li>3 Stocks That Could Be Next to Announce a Stock Split</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只可能下一个宣布股票拆分的股票</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Obsidian Personal Planning Solutions LLC boosted its stake in McKesson by 2.9% in the 3rd quarter. Obsidian Personal Planning Solutions LLC now owns 426 shares of the company's stock worth $346,000 after purchasing an additional 12 shares during the period. IAM Advisory LLC boosted its stake in McKesson by 0.3% in the 3rd quarter. IAM Advisory LLC now owns 3,908 shares of the company's stock worth $3,019,000 after purchasing an additional 13 shares during the period. PDS Planning Inc boosted its stake in McKesson by 1.1% in the 3rd quarter. PDS Planning Inc now owns 1,209 shares of the company's stock worth $934,000 after purchasing an additional 13 shares during the period. Berkshire Asset Management LLC PA boosted its stake in McKesson by 4.6% in the 3rd quarter. Berkshire Asset Management LLC PA now owns 294 shares of the company's stock worth $227,000 after purchasing an additional 13 shares during the period. Finally, Norden Group LLC boosted its stake in McKesson by 4.3% in the 4th quarter. Norden Group LLC now owns 317 shares of the company's stock worth $260,000 after purchasing an additional 13 shares during the period. Institutional investors and hedge funds own 85.07% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者最近也增加或减少了在该公司的持股。Obsidian Personal Planning Solutions LLC 在第三季度将其在麦克森的持股比例提高了 2.9%。Obsidian Personal Planning Solutions LLC 现在持有 426 股该公司的股票，价值 346,000 美元，此前在此期间购买了额外的 12 股。IAM Advisory LLC 在第三季度将其在麦克森的持股比例提高了 0.3%。IAM Advisory LLC 现在持有 3,908 股该公司的股票，价值 3,019,000 美元，此前在此期间购买了额外的 13 股。PDS Planning Inc 在第三季度将其在麦克森的持股比例提高了 1.1%。PDS Planning Inc 现在持有 1,209 股该公司的股票，价值 934,000 美元，此前在此期间购买了额外的 13 股。Berkshire Asset Management LLC PA 在第三季度将其在麦克森的持股比例提高了 4.6%。Berkshire Asset Management LLC PA 现在持有 294 股该公司的股票，价值 227,000 美元，此前在此期间购买了额外的 13 股。最后，Norden Group LLC 在第四季度将其在麦克森的持股比例提高了 4.3%。Norden Group LLC 现在持有 317 股该公司的股票，价值 260,000 美元，此前在此期间购买了额外的 13 股。机构投资者和对冲基金持有该公司 85.07% 的股份。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of research firms recently commented on MCK. Morgan Stanley reaffirmed an &#34;overweight&#34; rating and issued a $966.00 price objective on shares of McKesson in a research note on Thursday, January 29th. TD Cowen raised their price objective on shares of McKesson from $1,000.00 to $1,012.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, February 5th. Leerink Partners reaffirmed an &#34;outperform&#34; rating and issued a $1,085.00 price objective on shares of McKesson in a research note on Thursday, March 5th. Robert W. Baird set a $968.00 price objective on shares of McKesson in a research note on Wednesday, January 14th. Finally, Weiss Ratings downgraded shares of McKesson from a &#34;buy (a-)&#34; rating to a &#34;buy (b+)&#34; rating in a research report on Thursday, February 5th. Thirteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and an average price target of $970.93.</p>
<div class="lb-trans"><p>一些研究公司最近对 MCK 进行了评论。摩根士丹利在 1 月 29 日的研究报告中重申了 “增持” 评级，并对麦克森的股票设定了 966.00 美元的目标价。TD Cowen 在 2 月 5 日的研究报告中将麦克森的目标价从 1,000.00 美元提高至 1,012.00 美元，并给予该股票 “买入” 评级。Leerink Partners 在 3 月 5 日的研究报告中重申了 “跑赢大盘” 评级，并对麦克森的股票设定了 1,085.00 美元的目标价。罗伯特·W·贝尔德在 1 月 14 日的研究报告中设定了 968.00 美元的目标价。最后，Weiss Ratings 在 2 月 5 日的研究报告中将麦克森的股票评级从 “买入（a-）” 下调至 “买入（b+）”。十三位分析师对该股票给予了买入评级，三位分析师对该股票给予了持有评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，平均目标价为 970.93 美元。</p>
</div><ul>
<li>3 Dividend Growth Stocks Quietly Raising Payouts</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只安静提高分红的增长股票</li>
</ul>
</div><p><strong>View Our Latest Research Report on McKesson</strong></p>
<div class="lb-trans"><p><strong>查看我们关于麦克森的最新研究报告</strong></p>
</div><h2>Key Headlines Impacting McKesson</h2>
<div class="lb-trans"><h2>影响麦克森的关键头条新闻</h2>
</div><p>Here are the key news stories impacting McKesson this week:</p>
<div class="lb-trans"><p>以下是本周影响麦克森的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Apollo to buy a minority stake (~13%) in McKesson’s Medical‑Surgical Solutions business for $1.25 billion — validates the MMS spinoff plan, provides liquidity ahead of the IPO, and brings an external investor endorsement that may de‑risk the separation. McKesson sells minority stake in surgical supplies unit to Apollo Funds for $1.25 billion</li>
<li>Positive Sentiment: Company press release/coverage confirms the definitive agreement with Apollo and frames the transaction as a milestone toward the planned MMS IPO — signals management is executing the separation strategy and unlocking value. McKesson Signs Agreement with Apollo Funds for Strategic Minority Interest in Medical-Surgical Solutions</li>
<li>Positive Sentiment: Analysts expect McKesson to report another strong quarter next month with projected double‑digit profit growth — a near‑term catalyst that could reverse weakness if results beat expectations. McKesson Earnings Preview: What to Expect</li>
<li>Neutral Sentiment: Longer‑term analyst pieces highlight McKesson’s compounding track record (double‑digit EPS growth and management’s shareholder value creation) — supportive for investors focused on multi‑year returns but less immediately market‑moving. Is McKesson Stock Still A High-Conviction Compounder?</li>
<li>Neutral Sentiment: Standalone comparisons and sector articles (e.g., head‑to‑head with CONMED) provide context but are unlikely to move the stock materially by themselves. McKesson versus CONMED Head to Head Comparison</li>
<li>Negative Sentiment: Market reaction: coverage notes McKesson is trading down more than the broader market today — the stock has pulled back from near‑term highs as investors digest the MMS transaction details, timing of the spinoff, and broader market moves. McKesson (MCK) Sees a More Significant Dip Than Broader Market</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：阿波罗将以 12.5 亿美元收购麦克森医疗 - 外科解决方案业务的少数股权（约 13%）——验证了 MMS 分拆计划，为 IPO 提供流动性，并带来外部投资者的认可，可能降低分拆的风险。麦克森将少数股权出售给阿波罗基金，交易额为 12.5 亿美元</li>
<li>积极情绪：公司新闻稿/报道确认与阿波罗的最终协议，并将交易框架视为计划中的 MMS IPO 的里程碑——表明管理层正在执行分拆战略并释放价值。麦克森与阿波罗基金签署战略少数股权协议，涉及医疗 - 外科解决方案</li>
<li>积极情绪：分析师预计麦克森下个月将报告另一个强劲的季度，预计利润将实现两位数增长——如果结果超出预期，这将成为短期催化剂，可能逆转疲软。麦克森财报预览：预期是什么</li>
<li>中性情绪：长期分析师文章强调麦克森的复合增长记录（每股收益两位数增长和管理层的股东价值创造）——对关注多年回报的投资者支持，但对市场的即时影响较小。麦克森股票仍然是高信念的复合增长股吗？</li>
<li>中性情绪：独立比较和行业文章（例如，与 CONMED 的正面比较）提供了背景，但不太可能单独对股票产生实质性影响。麦克森与 CONMED 的正面比较</li>
<li>消极情绪：市场反应：报道指出麦克森今天的交易下跌幅度超过大盘——由于投资者消化 MMS 交易的细节、分拆的时机以及更广泛的市场走势，该股票已从近期高点回落。麦克森（MCK）下跌幅度超过大盘</li>
</ul>
</div><h2>McKesson Stock Down 1.9%</h2>
<div class="lb-trans"><h2>麦克森股票下跌 1.9%</h2>
</div><ul>
<li>More Than Yield: 5 Stocks Beating the Market and Hiking Dividends</li>
</ul>
<div class="lb-trans"><ul>
<li>超过收益：5 只击败市场并提高分红的股票</li>
</ul>
</div><p>MCK stock opened at $842.59 on Wednesday. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00. The company has a market cap of $103.21 billion, a price-to-earnings ratio of 24.23, a PEG ratio of 1.24 and a beta of 0.42. The company has a 50 day moving average of $910.28 and a two-hundred day moving average of $856.99.</p>
<div class="lb-trans"><p>MCK 股票周三开盘价为 842.59 美元。麦克森公司 12 个月低点为 637.00 美元，12 个月高点为 999.00 美元。该公司的市值为 1,032.1 亿美元，市盈率为 24.23，PEG 比率为 1.24，贝塔值为 0.42。该公司的 50 日移动平均线为 910.28 美元，200 日移动平均线为 856.99 美元。</p>
</div><p>McKesson (NYSE:MCK - Get Free Report) last released its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $9.19 by $0.15. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The company had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. During the same quarter in the prior year, the firm earned $8.03 EPS. The company's revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, research analysts anticipate that McKesson Corporation will post 39.02 EPS for the current year.</p>
<div class="lb-trans"><p>麦克森（NYSE:MCK - 获取免费报告）最近于 2 月 4 日（星期三）发布了其财报。公司报告本季度每股收益（EPS）为 9.34 美元，超出分析师一致预期的 9.19 美元，超出幅度为 0.15 美元。麦克森的净利润率为 1.09%，股本回报率为负的 338.97%。本季度公司收入为 1061.6 亿美元，而一致预期为 1059.8 亿美元。去年同期，公司每股收益为 8.03 美元。与去年同期相比，公司的收入增长了 11.4%。麦克森已将 2026 财年的指引设定为 38.800-39.200 的每股收益。研究分析师平均预计麦克森公司今年将发布 39.02 的每股收益。</p>
</div><h2>McKesson Dividend Announcement</h2>
<div class="lb-trans"><h2>麦克森分红公告</h2>
</div><p>The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd were issued a dividend of $0.82 per share. The ex-dividend date was Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. McKesson's dividend payout ratio (DPR) is currently 9.43%.</p>
<div class="lb-trans"><p>该公司最近宣布了一项季度分红，已于 4 月 1 日（星期三）支付。3 月 2 日（星期一）登记在册的股东获得每股 0.82 美元的分红。除息日期为 3 月 2 日（星期一）。这相当于年化分红为 3.28 美元，分红收益率为 0.4%。麦克森的分红支付比率（DPR）目前为 9.43%。</p>
</div><h2>Insider Buying and Selling at McKesson</h2>
<div class="lb-trans"><h2>麦克森内部买卖情况</h2>
</div><p>In other news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the firm's stock in a transaction on Friday, February 6th. The shares were sold at an average price of $955.00, for a total transaction of $313,240.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Maria Martinez sold 349 shares of the firm's stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $939.87, for a total transaction of $328,014.63. Following the transaction, the director owned 301 shares in the company, valued at $282,900.87. This represents a 53.69% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,592 shares of company stock worth $3,518,555 over the last quarter. Company insiders own 0.08% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席会计官纳波利昂·B·鲁特利奇（Napoleon B. Rutledge, Jr.）于 2 月 6 日（星期五）出售了 328 股公司的股票，交易价格为每股 955.00 美元，总交易额为 313,240.00 美元。该交易已在向 SEC 提交的文件中披露，相关文件可通过此链接访问。此外，董事玛丽亚·马丁内斯（Maria Martinez）于 2 月 19 日（星期四）出售了 349 股公司的股票，交易价格为每股 939.87 美元，总交易额为 328,014.63 美元。交易后，该董事在公司持有 301 股，价值 282,900.87 美元。这代表其持股比例减少了 53.69%。该销售的 SEC 文件提供了更多信息。内部人士在上个季度共出售了 3,592 股公司股票，价值 3,518,555 美元。公司内部人士持有公司股票的比例为 0.08%。</p>
</div><h2>McKesson Company Profile</h2>
<div class="lb-trans"><h2>麦克森公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.</p>
<div class="lb-trans"><p>麦克森公司（NYSE: MCK）是一家全球医疗服务和分销公司，提供药品、医疗外科产品和医疗技术解决方案。公司成立于 1833 年，总部位于德克萨斯州的欧文，麦克森在药品分销和医疗服务价值链中运营，连接制造商、药店、医院和医疗系统，以帮助管理药物和临床供应的流动。</p>
</div><p>The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.</p>
<div class="lb-trans"><p>公司的核心业务包括药品批发分销和物流、专业药房服务，以及向急性和非急性护理提供者提供医疗外科用品。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than McKesson</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过麦克森</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding MCK?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 MCK 感兴趣的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取麦克森公司（NYSE:MCK - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1DSw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=MCK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in McKesson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在麦克森吗？</h2>
</div><p>Before you consider McKesson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑麦克森之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and McKesson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而麦克森并不在名单上。</p>
</div><p>While McKesson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然麦克森目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

McKesson Corporation $MCK Position Increased by M&T Bank Corp

Market Beat

2 倍做空纳斯达克生物技术 ETF - ProShares

制药 ETF - VanEck Vectors

动态制药业投资组合 ETF - Invesco

医疗器械ETF永赢

华夏中证全指医疗器械ETF

易方达中证生物科技主题ETF

广发中证全指医药卫生ETF

招商中证生物科技主题ETF

纽交所高增长板生物技术指数 ETF - First Trust

美国制药 ETF - iShares

广发中证香港创新药(QDII-ETF)

动态生物技术与基因组 ETF - Invesco

华夏医药ETF

汇添富中证医药卫生ETF

纳斯达克生物科技指数 ETF - iShares Nasdaq

麦克森

M&T Bank

摩根士丹利

Apollo Global

康美公司

M & T BANK CORP DEP SHS REPSTG 1/400TH INT PERP SER K

M & T BANK CORP PERP NON CUM PFD FIXED FLTG RATE SER H

M & T BANK CORP DEP SHS EA REP 1/400TH SHS SERIES J

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

APOLLO GLOBAL MANAGEMENT INC 6.75% CONV PFD STK SER A

Apollo Global Management Pref Share APO 7.625 09/15/53

M&T Bank Corp 增加了对 McKesson Corporation $MCK 的持股量